Drug intelligence / Profile preview

tetravalent recombinant norovirus vaccine

Development stage: Phase 2
Lead developer: Anhui Zhifei Longcom Biopharmaceutical
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Injection

Overview

The tetravalent recombinant norovirus vaccine is designed to prevent norovirus infection by inducing an immune response against four specific norovirus genotypes: HuNoV GI.1, GII.3, GII.4, and GII.17. It contains recombinant VP1 proteins from each of these strains, expressed in *Pichia pastoris*. The vaccine is being developed by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. and is currently undergoing Phase I/IIa clinical trials to evaluate its safety, tolerability, and immunogenicity in various age groups, including infants, toddlers, adolescents, young adults, and the elderly.

Brand names: Yuan Da Sai Wei XinLongkoma Quadrivalent Recombinant Norovirus Vaccine
Other names: Longkoma Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris)

Targets

GI.1 VP1 (Norovirus GI.1 VP1)GII.4 VP1 (Norovirus GII.4 VP1)GII.17 VP1 (Norovirus GII.17 VP1)

Beyond the preview

Go deeper on tetravalent recombinant norovirus vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tetravalent recombinant norovirus vaccine.

Explore the full profile